Phase I Dose Escalation Study of Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-cell Acute Lymphoblastic Leukemia (B-ALL)

​ Conditions: B-All; Acute Lymphoblastic Leukemia

Interventions: Biological: TSLPR-CART; Drug: Cyclophosphamide; Drug: Fludarabine

Sponsors: National Cancer Institute (NCI)

Not yet recruiting Conditions: B-All; Acute Lymphoblastic Leukemia
Interventions: Biological: TSLPR-CART; Drug: Cyclophosphamide; Drug: Fludarabine
Sponsors: National Cancer Institute (NCI)
Not yet recruiting